Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 1:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 234 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: schizophrenia/schizoaffective disorder. Clear all
Completed Phase 1 Interventional

Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

NCT02411526
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
ZX003 (Risperidone-SABER®), Risperdal Consta, Oral Risperidone
Drug
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 12, 2026, 1:20 AM EDT
Completed Phase 4 Interventional

A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia

NCT00222794
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Atomoxetine (Strattera)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Oct 12, 2026, 1:20 AM EDT
Completed Phase 3 Interventional Results available

High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms

NCT00403546
View directory record Official record
Conditions
Schizophrenia
Interventions
Ziprasidone 80-160 mg/d, Placebo, Ziprasidone 160 mg/d
Drug
Lead sponsor
Donald C. Goff, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
9
States / cities
Augusta, Georgia • Fall River, Massachusetts • Grand Rapids, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 12, 2026, 1:20 AM EDT
Completed Not applicable Interventional Results available

Cognitive Adaptive Training for Improving Medication Adherence, Symptoms, and Function in People With Schizophrenia

NCT00455663
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive Adaptation Training, Pharm-Cognitive Adaptation Training, Treatment as usual
Behavioral · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 60 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 12, 2026, 1:20 AM EDT
Completed Phase 4 Interventional Results available

The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)

NCT00816907
View directory record Official record
Conditions
Schizophrenia
Interventions
Metformin, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Palo Alto, California • Boca Raton, Florida • Iowa City, Iowa + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2013 · Synced Oct 12, 2026, 1:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuroimaging of Dopamine Metabolism in Normal and Psychiatric Patients

NCT00001320
View directory record Official record
Conditions
Healthy, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 12, 2026, 1:20 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder

NCT00061802
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
risperidone, quetiapine
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
San Diego, California • Hoffman Est, Illinois • Lake Charles, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 12, 2026, 1:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Peripheral Immune System in Individuals With Schizophrenia

NCT05109065
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders
Interventions
SCID (Standardized Clinical Interview for DSM-V), PSS (Perceived Stress Score), Urine Toxicology Screen, Vitals, Blood Work, PQ-B, COVID Screening, Positive and Negative Syndrome Scale (PANSS)
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 40 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 12, 2026, 1:20 AM EDT
Completed Phase 2 Interventional

A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders

NCT00650611
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
17
States / cities
San Diego, California • Altamonte Springs, Florida • Libertyville, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 12, 2026, 1:20 AM EDT
Withdrawn Not applicable Interventional

Home-based Exercise for SMI

NCT06078293
View directory record Official record
Conditions
Serious Mental Illness
Interventions
Home-based Exercise Program
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 12, 2026, 1:20 AM EDT
Completed Not applicable Interventional Results available

Probiotics to Prevent Relapse After Hospitalization for Mania

NCT01731171
View directory record Official record
Conditions
Bipolar Disorder, Schizoaffective Disorder
Interventions
Probiotic Supplement, Inert Compound
Dietary Supplement
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 12, 2026, 1:20 AM EDT
Completed Phase 2Phase 3 Interventional

High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder

NCT00297947
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine
Drug
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 12, 2026, 1:20 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

NEURO-COGS: Neurometabolic Mechanisms of Cognitive Training in Schizophrenia

NCT07788755
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Cognitive Impairment, Visual Impairment
Interventions
Perceptual Discrimination Training, Cognitive Control Training
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 79 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 12, 2026, 1:20 AM EDT
Not listed Phase 4 Interventional

Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder

NCT03857581
View directory record Official record
Conditions
Psychosis, Substance Use Disorders
Interventions
Clozapine, Olanzapine
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Evans, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 12, 2026, 1:20 AM EDT
Completed Phase 4 Interventional

Feasibility of Providing Cognitive Remediation to People With Schizophrenia in a Clinical Network

NCT00930150
View directory record Official record
Conditions
Schizophrenia
Interventions
Targeted cognitive training, Computer control, Bridging groups, Health and wellness groups
Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
New Haven, Connecticut • Atlanta, Georgia • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 12, 2026, 1:20 AM EDT
Completed Phase 4 Interventional Results available

Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder

NCT00190749
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 4, 2010 · Synced Oct 12, 2026, 1:20 AM EDT
Completed Not applicable Interventional

Evaluation of mHealth for Serious Mental Illness

NCT04068467
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Major Depressive Disorder, Bipolar Disorder
Interventions
Smartphone App, Waitlist Control
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 12, 2026, 1:20 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder

NCT04779177
View directory record Official record
Conditions
Schizophrenia, Pediatric
Interventions
Lumateperone 42 mg, Lumateperone 28 mg
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Hollywood, Florida • Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 12, 2026, 1:20 AM EDT
Recruiting No phase listed Observational

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383
View directory record Official record
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia, Delusional Disorder, Bipolar 1 Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified, Early Psychosis
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 12, 2026, 1:20 AM EDT
Completed Phase 2 Interventional Results available

Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

NCT02237235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
MMFS-202-302, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 12, 2026, 1:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Knowledge and Perception of Smoking Risks/Consequences

NCT00686101
View directory record Official record
Conditions
Cigarette Smoking, Schizophrenia
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 12, 2026, 1:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography

NCT00942981
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia
Interventions
PET
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 90 Years
Enrollment
283 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 12, 2026, 1:20 AM EDT
Completed Phase 3 Interventional Results available

Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder

NCT00644969
View directory record Official record
Conditions
Smoking Cessation
Interventions
placebo, varenicline (CP-526,555)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
Aurora, Colorado • Farmington, Connecticut • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 12, 2026, 1:20 AM EDT
Completed Not applicable Interventional Results available

Personalized and Scalable Cognitive Remediation Approaches

NCT01945333
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cognitive remediation
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
Brooklyn, New York • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 12, 2026, 1:20 AM EDT